XNW28012

Phase 1Small molecule

EEvopoint Biosciences Inc.

XNW28012 is one of 3 small molecule programs targeting Metastatic Pancreatic Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Pancreatic CancerNot yet recruiting

Metastatic Pancreatic CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Metastatic Pancreatic Cancer

#DrugCompanyPhaseTrials

GFH375

GGenfleet Therapeutics (Shanghai) Inc.

Phase 3

1 2

Ga DOTA

UUniversity of California, Davis

Phase 1

1 3

XNW28012

EEvopoint Biosciences Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06799637

Q2 2028

Phase 1Not yet recruiting

Metastatic Pancreatic Cancer

NCT07707674

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments

Recruiting·EEvopoint Biosciences Inc.·Phase 1/2·NCT06799637·200 enrolled

Metastatic Pancreatic Cancer1 trial

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects With Metastatic Pancreatic Cancer

Not yet recruiting·EEvopoint Biosciences Inc.·Phase 1·NCT07707674·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for XNW28012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XNW28012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XNW28012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Evopoint Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEvopoint Biosciences Inc.

XNW28012

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

Advanced Solid Tumors1 trial

Metastatic Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News